Appendix G

Article Content Abstraction Form

Treatment of Coexisting Cataract & Glaucoma

Content Assessment

Article ID: __________			

First Author (Last Name): ___________________________

Reviewer 1: __________			

Reviewer 2: __________

DESCRIPTION OF STUDY GROUPS

1.  Number of groups in the study: __________

2.  For each group, provide a brief description of the group (e.g., trabeculectomy and cataract):

Group	Description (e.g., surgical technique or other basis of group differences)

A	

B	

C	

D	

3.  Specific Aim(s):  Provide a brief statement describing the specific aim(s) of the study.

	TREATMENTS

4.  For each group, indicate the treatment or treatments received, by checking the appropriate box or boxes. Where “other” is selected, indicate on the space provided, the nature of the other treatment.  For each group in the study, at least one box must be filled.

 Treatment(s)

	Group A	Group B	Group C	Group D

Indicate

treatment or treatment(s) received for all groups	☐ Trabeculoplasty

☐ Trabeculectomy

☐ Endoscopic Laser

☐ Cataract Extraction

☐ Anti-fibrosis Agents

☐ Other Medications

☐ Other____________

☐ Not Applicable	☐ Trabeculoplasty

☐ Trabeculectomy

☐ Endoscopic Laser

☐ Cataract Extraction

☐ Anti-fibrosis Agents

☐ Other Medications

☐ Other____________

☐ Not Applicable	☐ Trabeculoplasty

☐ Trabeculectomy

☐ Endoscopic Laser

☐ Cataract Extraction

☐ Anti-fibrosis Agents

☐ Other Medications

☐ Other____________

☐ Not Applicable	☐ Trabeculoplasty

☐ Trabeculectomy

☐ Endoscopic Laser

☐ Cataract Extraction

☐ Anti-fibrosis Agents

☐ Other Medications

☐ Other____________

☐ Not Applicable

5.  Indicate the number of different surgeons participating in the study: _______________  ☐ Can’t Tell/Not Stated

Trabeculoplasty

 If no groups received trabeculoplasty, GO TO Question 10, Page 4

6.  For each group receiving TRABECULOPLASTY, indicate the wavelength of light used (check only one box).	

Wavelength	Group A	Group B	Group C	Group D

	☐ Green

☐ Blue

☐ Red

☐ Diode

☐ Can’t Tell	☐ Green

☐ Blue

☐ Red

☐ Diode

☐ Can’t Tell	☐ Green

☐ Blue

☐ Red

☐ Diode

☐ Can’t Tell	☐ Green

☐ Blue

☐ Red

☐ Diode

☐ Can’t Tell

7.  For each group receiving TRABECULOPLASTY, indicate the degrees of angle treated.  Where “other” is chosen, indicate the degrees of angle treated in the space provided.

Degrees of Angle Treated	Group A	Group B	Group C	Group D

	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell

8.  For each group receiving TRABECULOPLASTY, indicate the laser power in milliwatts.

Laser power	Group A	Group B	Group C	Group D

                           MW 

☐ Can’t Tell	

                           MW 

☐ Can’t Tell	

                           MW 

☐ Can’t Tell	

                           MW 

☐ Can’t Tell

9.  Trabeculoplasty Comments:

Trabeculectomy

 If no groups received Trabeculectomy, GO TO Question 12

10.  For each group receiving TRABECULECTOMY, indicate the incision location (check only one box)

Location of Incision

	Group A	Group B	Group C	Group D

	☐ Limbus

☐ Fornix

☐ Can’t Tell	☐ Limbus

☐ Fornix

☐ Can’t Tell	☐ Limbus

☐ Fornix

☐ Can’t Tell	☐ Limbus

☐ Fornix

☐ Can’t Tell

11.  Trabeculectomy Comments:

Anti-Fibrosis Agents

If no group received Anti-Fibrosis Agents, GO TO Question 16, Page 6

12.  For each group receiving Mitomycin-C, indicate dose, duration & number of patients receiving.

Mitomycin-C

	Group A	Group B	Group C	Group D

12a. Group received Mitomycin-C ?	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell

12b. Mitomycin-C, Concentration	☐ 0.1 mg/ml

☐ 0.2 mg/ml

☐ 0.3 mg/ml

☐ 0.4 mg/ml

☐ 0.5 mg/ml

☐ Can’t Tell	☐ 0.1 mg/ml

☐ 0.2 mg/ml

☐ 0.3 mg/ml

☐ 0.4 mg/ml

☐ 0.5 mg/ml

☐ Can’t Tell	☐ 0.1 mg/ml

☐ 0.2 mg/ml

☐ 0.3 mg/ml

☐ 0.4 mg/ml

☐ 0.5 mg/ml

☐ Can’t Tell	☐ 0.1 mg/ml

☐ 0.2 mg/ml

☐ 0.3 mg/ml

☐ 0.4 mg/ml

☐ 0.5 mg/ml

☐ Can’t Tell

12c. Mitomycin-C, Duration	☐ <1 minute

☐ 1-1.9 minute

☐ 2-2.9 minutes

☐ 3-3.9 minutes

☐ 4-4.9 minutes

☐ >5 minutes

☐ Can’t Tell	☐ <1 minute

☐ 1-1.9 minute

☐ 2-2.9 minutes

☐ 3-3.9 minutes

☐ 4-4.9 minutes

☐ >5 minutes

☐ Can’t Tell	☐ <1 minute

☐ 1-1.9 minute

☐ 2-2.9 minutes

☐ 3-3.9 minutes

☐ 4-4.9 minutes

☐ >5 minutes

☐ Can’t Tell	☐ <1 minute

☐ 1-1.9 minute

☐ 2-2.9 minutes

☐ 3-3.9 minutes

☐ 4-4.9 minutes

☐ >5 minutes

☐ Can’t Tell

12d. Mitomycin-C, 

Number Receiving 	

☐ Can’t Tell	

☐ Can’t Tell	

☐ Can’t Tell	

☐ Can’t Tell

13.  For all groups receiving 5-Fluorouracil intraoperatively, complete all relevant rows for each relevant group.  Where necessary, indicate concentration, dose, and duration.

Intraoperative 5-Fluorouracil

	Group A	Group B	Group C	Group D

13a. Group received 5-Fluorouracil?	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell

13c. 5-Fluorouracil method of administration.	☐ Sponge

☐ Injection

☐ Can’t Tell	☐ Sponge

☐ Injection

☐ Can’t Tell	☐ Sponge

☐ Injection

☐ Can’t Tell	☐ Sponge

☐ Injection

☐ Can’t Tell

13d. 5-Fluorouracil, on sponge

concentration, if other than 50mg/ml.	mg/ml

☐ Can’t Tell	mg/ml

☐ Can’t Tell	mg/ml

☐ Can’t Tell	mg/ml

☐ Can’t Tell

13e.  5-Fluorouracil, on sponge

duration, if other than 5 minutes.	

                 min.

☐ Can’t Tell	

                 min.

☐ Can’t Tell	

                 min.

☐ Can’t Tell	

                 min.

☐ Can’t Tell

13f. 5-Fluorouracil, injection dose (mg.), if other than 5 mg.	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell

14.  Did any groups receive 5-Fluorouracil postoperatively?  If so, for each relevant group, indicate dose and number of injections. 

Postoperative 5- Fluorouracil

	Group A	Group B	Group C	Group D

14a. Group received 5-Fluorouracil?	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell	☐ Yes

☐ Can’t Tell

14b. 5-Fluorouracil, Dose (mg.)	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell	

                   mg.

☐ Can’t Tell

14c. 5-Fluorouracil, Number of Injections	

☐ Can’t Tell	

☐ Can’t Tell	

☐ Can’t Tell	

☐ Can’t Tell

15.  Anti-Fibrosis Agents, Comments:

Endoscopic Laser

If no groups received Endoscopic Laser, GO TO Question 19

16. For each group receiving ENDOSCOPIC LASER, indicate the degrees of angle treated.  Where “other” is chosen, indicate the degrees of angle treated in the space provided.

Degrees of Angle Treated	Group A	Group B	Group C	Group D

	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell	☐ 90

☐ 180

☐ 360

☐ Other ___________

☐ Can’t Tell

17.  For each group receiving ENDOSCOPIC LASER, indicate the total energy used, in milliwatts.

Endolaser power	Group A	Group B	Group C	Group D

                            mw

☐ Can’t Tell	

                            mw

☐ Can’t Tell	

                            mw

☐ Can’t Tell	

                            mw

☐ Can’t Tell

18.  Endoscopic Laser Comments:

Cataract Extraction

If no groups received cataract extraction, GO TO Question 22, Page 8

19. For all groups receiving CATARACT EXTRACTION check the box corresponding to the cataract extraction technique used (check only one box).  If “other” is selected, indicate the cataract extraction technique in the space provided

Cataract

Extraction	Group A	Group B	Group C	Group D

	☐ ECCE

☐ Phacoemulsification

☐ Other____________

☐ Can’t Tell	☐ ECCE

☐ Phacoemulsification

☐ Other____________

☐ Can’t Tell	☐ ECCE

☐ Phacoemulsification

☐ Other____________

☐ Can’t Tell	☐ ECCE

☐ Phacoemulsification

☐ Other____________

☐ Can’t Tell

20.  For each group receiving CATARACT EXTRACTION, indicate the type of incision used (check all that apply).

Incision	Group A	Group B	Group C	Group D

	☐ Scleral 

☐ Clear Cornea

☐ One Site Combined

☐ Two Site Combined

☐ Can’t Tell	☐ Scleral

☐ Clear Cornea

☐ One Site Combined

☐ Two Site Combined

☐ Can’t Tell	☐ Scleral

☐ Clear Cornea

☐ One Site Combined

☐ Two Site Combined

☐ Can’t Tell	☐ Scleral

☐ Clear Cornea

☐ One Site Combined

☐ Two Site Combined

☐ Can’t Tell

21.  Cataract Extraction Comments:

INTRAOPERATIVE & IMMEDIATE POSTOPERATIVE MEDICATIONS

Complete this section (questions 22, 23, 24, & 25) 

ONLY for RCTs concerning acute 24 hour IOP. 

Otherwise, GO TO Question 26, Page 10

22.  Indicate Medications Used Intraoperatively.  If none of the listed medications were used intraoperatively, check the box in 22a to indicate this. 

Intraoperative

Medications	Group A	Group B	Group C	Group D

22a. ☐ None Stated				

22b. Acetylcholine (Miochol)

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

22c. Carbachol (Miostat)

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

22d.  Other (specify)

23.  Indicate those groups in which viscoelastic was used intraoperatively.  If not used intraoperatively, please indicate this by checking the box in the column labeled “viscoelastic used intraoperatively?”.

Viscoelastic Used Intraoperatively?	Group A	Group B	Group C	Group D

☐ Viscoelastic not used

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

24.  Indicate Medications Used Immediately Postoperatively.    If none of the listed medications were used postoperatively, check the box in 24a to indicate this.

Immediate Postoperative

Medications	Group A	Group B	Group C	Group D

24a. ☐ None Used				

24b. Alpha agonist

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

24c. Beta blocker 

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

24d. Pilocarpine

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

24e. Acetazolamide

☐ Not Reported by Group	☐ Yes

	☐ Yes

	☐ Yes

	☐ Yes

24d. Other (specify)

25.  Intraoperative & Postoperative Medications Comments:

Patient /Study Demographic Characteristics

26.  In what part of the world was the study mainly performed?

	☐ US

	☐ Canada

	☐ Europe

	☐ Other, (specify): ______________________________

	☐ Can’t Tell/Unknown

27.  Study Exclusion Criteria, check all that apply.  For other, indicate the exclusion criterion.

	☐ None specified

	☐ Previous glaucoma laser (PI or LTP) ____________________________________________

	☐ Previous glaucoma surgery (e.g, trabeculectomy) ________________________________

	☐ Previous cataract surgery

	☐ Age < _______ years

	☐ Inflammatory glaucoma

	☐ Neovascular glaucoma

	☐ Other: ________________________________________

	☐ Other: ________________________________________

28.  For each, indicate the number of patients in each group.  If information is provided, but not reported by group, indicate the total number of study patients with that demographic in the column labeled “participant demographics”.

Participant Demographics	Group A	Group B	Group C	Group D

28a. Number of patients

☐ Not reported by group, if true indicate total number of patients:

28b. Number of eyes

☐ Not reported by group, if true indicate total number of eyes:

28c. Males

☐ Not given by group, if true, indicate total number of male subjects:

28d. Age

☐ Not reported by group, if true indicate mean overall age:

28e. Ethnicity

☐ Not reported				

28f. White  

☐ Not reported by group, if true indicate total number of white subjects:

28g. Black  

☐ Not reported by group, if true indicate total number of black subjects:

28h. Hispanic  

☐ Not reported by group, if true, indicate total number of Hispanic subjects:

28i. Asian 

☐ Not reported by group, if true, indicate total number of Asian subjects:

28j. Other Race/Ethnicity

☐ Not reported by group, if true, indicate total number of subjects  from other race groups:

29.  Patient Demographic Characteristics Comments:				

Patient/Study Ocular Characteristics

30.  Number of prior conjunctival surgeries

Prior Conjunctival Surgeries	Group A	Group B	Group C	Group D

30a Mean number of prior conjunctival surgeries, per eye, by group  

☐ Not reported

☐ Not reported by group, if true then provide overall mean prior surgeries:

30b. Number of eyes with any prior conjunctival surgery

☐ Not reported 

☐ Not reported by group				

31.  Distribution of glaucoma by type.  For each group, fill out all relevant rows.

Glaucoma Type	Group A	Group B	Group C	Group D

31a. Number of eyes with primary open angle glaucoma (includes NTG)

☐ Not reported 

☐ Not reported by group				

31b. Number of eyes with exfoliation/capsular glaucoma

☐ Not reported 

☐ Not reported by group				

31c. Number of eyes with pigment dispersion glaucoma

☐ Not reported 

☐ Not reported by group				

31d. Number of eyes with closed angle glaucoma

☐ Not reported 

☐ Not reported by group				

32.  For each group, indicate the total number of eyes with severe preoperative optic nerve damage.

Severe preoperative optic nerve damage	Group A	Group B	Group C	Group D

☐ Not reported 

☐ Not reported by group				

33.  For each group, indicate the total number of eyes with severe visual field defect.

Severe visual field defect	Group A	Group B	Group C	Group D

☐ Not reported 

☐ Not reported by group				

34.  Preoperative Glaucoma Medications Used.  For each group, fill out all relevant rows.

Preoperative Glaucoma Medications	Group A	Group B	Group C	Group D

34a.  For each group, indicate mean number of glaucoma medications

☐ Not reported 

☐ Not reported by group				

34b.  Number of eyes on preoperative glaucoma medications, per group

☐ Not reported

☐ Not reported by group				

35. Patient/Study Ocular Characteristics Comments:

GLAUCOMA SURGERY OUTCOMES

36.  Length of study followup: for each column, check one box in the pertinent columns.

Length of Study Followup		minimum		mean		median

< 24 hours	☐	☐	☐

> 24 hours but < 1 week	☐	☐	☐

> 1 week but < 1 month	☐	☐	☐

1 -< 3 months	☐	☐	☐

3 -< 6 months	☐	☐	☐

6 -< 12 months	☐	☐	☐

12 -< 24 months	☐	☐	☐

> 24 months	☐	☐	☐

37.  Preoperative IOP: Enter the mean and/or median IOP.  If not reported by group, enter the overall study mean and/or median IOP in the column labeled “Preoperative IOP.”

Preoperative IOP	Group A	Group B	Group C	Group D

37a. Mean preoperative IOP

☐ Not reported

☐ Not reported by group, if true, overall mean preop. IOP:

                                           mmHg	

                 mmHg	

                 mmHg	

                 mmHg	

                 mmHg

37b. Median preoperative IOP

☐ Not reported

☐ Not reported by group, if true, overall median preop. IOP:

                                           mmHg	

                 mmHg	

                 mmHg	

                 mmHg	

                 mmHg

38.  For each group, indicate the number of eyes requiring pupil manipulation.  If not reported, or not reported by group, check the appropriate box.

Pupil Manipulation	Group A	Group B	Group C	Group D

☐ Not reported

☐ Not reported by group				

39.  For each group, indicate the number of eyes requiring bleb needling.  If not reported, or not reported by group, check the appropriate box.

Bleb Needling	Group A	Group B	Group C	Group D

☐ Not reported

☐ Not reported by group				

40.  Cumulative postoperative IOP 24-hours of surgery (If Study Is Not RCT Concerning Acute IOP Elevation Only, GO TO Question 42).  Otherwise, for each group, fill out all relevant rows for the 24-hour postoperative IOP measurement. 

24-Hour Postoperative IOP	Group A	Group B	Group C	Group D

40a.  Mean IOP (mmHg)

☐ Not reported

☐ Not reported by group, if true, overall mean 24-hour postop IOP.	

                 mmHg	

                 mmHg	

                 mmHg	

                 mmHg

If 37a (mean preoperative IOP), and 40a (mean 24 hour IOP) are completed then skip 40b and 40c.  Otherwise, for 40b and 40c indicate the direction and magnitude of the IOP change (if IOP increased over time check +, if IOP decreased over time check -).

40b.  Mean IOP Change

☐ Not reported

☐ Not reported by group, if true, overall mean IOP change:

	☐+

☐ -	☐+

☐ -	☐+

☐ -	☐+

☐ -

40c.  Mean percent IOP change	☐+

☐ -	☐+

☐ -	☐+

☐ -	☐+

☐ -

40d.  Number of eyes with decrease in IOP				

40e.  Number of eyes with 0-10 mmHg increase in IOP				

40f.  Number of eyes with 11-20 mmHg increase in IOP				

40g.  Number of eyes with >20 mmHG increase in IOP 				

40h.  Number of eyes with IOP <21 mmHg				

40i.  Number of eyes with IOP 21-30 mmHg				

40j.  Number of eyes with IOP 31-40 mmHg				

40k.  Number of eyes with IOP >40 mmHg				

41.  Comments:

IF RCT OF ACUTE IOP CHANGES, STOP.

42.  Postoperative IOP: For each group, fill out all relevant rows for the last study followup duration at which 50% of eyes remained for postoperative IOP measurement.  In 42a., indicate the time from surgery, in days, when this followup measurement occurred.

Postoperative IOP	Group A	Group B	Group C	Group D

42a. Indicate the last duration of time after surgery at which 50% of eyes remained for followup (in days).

42b.  Number of eyes remaining

42c.  Mean IOP (mmHg)

☐ Not reported by group, if true, overall mean IOP at last followup.

If 37a (mean preoperative IOP), and 42c (mean postoperative IOP) are completed then skip 42d and 42e.  Otherwise, for 42d and 42e indicate the direction and magnitude of the IOP change (if IOP increased over time check +, if IOP decreased over time check -).

42d.  Mean change in IOP (mmHg)

☐ Not reported by group, if true, overall mean change in IOP at last followup.

	☐+

☐ -	☐+

☐ -	☐+

☐ -	☐+

☐ -

42e. Mean percent IOP (mmHg) change	☐+

☐ -	☐+

☐ -	☐+

☐ -	☐+

☐ -

42f.  Number of eyes achieving 30% IOP reduction				

42g.  Number of eyes achieving IOP < 21 mmHg				

42h.  Number of eyes achieving preset target IOP				

43.  Postoperative IOP Comments:

44.  Postoperative Glaucoma Medications:  For each group, fill out all relevant rows for the last study followup duration at which 50% of eyes remained for postoperative glaucoma medications.

Postoperative Glaucoma Medications	Group A	Group B	Group C	Group D

44a. Mean number of glaucoma medications at followup.

☐ Not reported 

☐ Not reported by group				

If 34a (mean number of preoperative glaucoma medications) and 44a (mean number of postoperative glaucoma medications) are complete, then skip 44b.  Otherwise, indicate for each group the direction and magnitude of the mean change in number of glaucoma medications.

44b. Mean change in number of glaucoma medications:

☐ Not reported 

☐ Not reported by group	☐+

☐ -	☐+

☐ -	☐+

☐ -	☐+

☐ -

44c. Number of eyes receiving glaucoma medications

☐ Not reported 

☐ Not reported by group				

45.  Number of eyes requiring repeat IOP-lowering surgery (trabeculectomy, drainage device, cyclodestruction).

Further IOP lowering surgery required	Group A	Group B	Group C	Group D

☐ Not reported 

☐ Not reported by group				

46.  Postoperative Visual Acuity: For each group, fill out all relevant rows for the last study followup duration at which 50% of eyes remained for postoperative visual acuity.

Postoperative Visual Acuity	Group A	Group B	Group C	Group D

46a.  Mean Postoperative Visual Acuity (report as Snellen equivalent)

☐ Not reported 

☐ Not reported by group				

46b.  Number of eyes with visual acuity 20/40 or better				

47.  Cataract formation (If cataract extraction was part of the study, GO TO Question, 48):  

Cataract formation	Group A	Group B	Group C	Group D

47a.  Number of eyes with  visually significant cataract

☐ Not reported 

☐ Not reported by group				

47b.  Number of eyes with postoperative decrease of at least 2 Snellen lines attributed to cataract.				

47c.  Number of eyes stated to have increase in lens opacity.				

47d.  Number of eyes requiring cataract surgery.

☐ Not reported 

☐ Not reported by group				

48. Glaucoma Surgery Outcomes Comments:

COMPLICATIONS			

49.  For each listed complication, indicate the number of eyes in each group for which the complication was reported.   If study did not report complications, fill in the box in 49a.

Complications	Group A	Group B	Group C	Group D

49a.  ☐ States "no complications"				

49b.  ☐ Does not mention complications. 				

49c.  Number of eyes with hypotony (IOP <5 at one month or more after surgery).

☐ Not reported by group				

49d.  Number of eyes with choroidal effusion (+/- requiring drainage)

☐ Not reported by group				

49e.  Number of eyes with 

hyphema.

☐ Not reported by group				

49f.  Number of eyes with hypotony maculopathy

☐ Not reported by group				

49g.  Number of eyes with 

early endophthalmitis

☐ Not reported by group				

49h.  Number of eyes with 

late endophthalmitis

☐ Not reported by group				

49i.  Number of eyes with wound leak requiring surgery

☐ Not reported by group				

49j.  Number of eyes with bleb leak (Seidel positive) (+/- surgery) during the first month after surgery  

☐ Not reported by group				

49k.  Number of eyes with bleb leak (Seidel positive) (+/- surgery) more than one month after surgery

☐ Not reported by group				

49l.  Number of eyes with cystoid macular edema

☐ Not reported by group				

49m.  Number of eyes with PC rupture/vitreous loss

☐ Not reported by group				

49n.  Number of eyes with Tenon’s cyst

☐ Not reported by group				

49o.  Number of eyes with supra- choroidal hemorrhage

☐ Not reported by group				

49p.  Number of eyes with corneal graft failure

☐ Not reported by group				

49q.  Number of eyes with corneal epithelial defect or ulceration

☐ Not reported by group				

49r.  Number of eyes with vitreous hemorrhage

☐ Not reported by group				

49s.  Number of eyes with posterior capsular opacification

☐ Not reported by group				

49t.  Number of eyes with fibrinous anterior chamber reaction

☐ Not reported by group				

49u.  ☐ States no additional complications encountered				

50.  Complications Comments:			

51. Study bottom line: Provide a brief statement describing the bottom line results of the study.